MedTrace Logo

Hemodiafiltration Versus Hemodialysis in Older People

NCT07278973 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-02-23

No results posted yet for this study

Summary

This study will compare the impact of two hemodialysis techniques on fatigue and post-dialysis recovery time in patients aged 85 years and older. These two techniques are high-flux hemodialysis (HD) and hemodiafiltration (HDF).

Patients will receive the treatment over two periods: if period 1 is HD then period 2 will be HDF. Every patient will be his/her own control, this is why it is called cross-over. Each period will last three months. Between the two periods, patients will receive a traditional low-flux hemodialysis.

These two techniques are widely used worldwide and their side-effects are well-known and do not put the patients at risk. HDF has been shown to improve survival in patients with a mean age of 58 years. But a previous study from the investigators' group showed that HDF causes a prolonged recovery time in older patients. This randomized trial aims to elucidate this question.

Conditions

  • Hemodialysis
  • Hemodiafiltration
  • Fatigue Symptom
  • Quality of Life of Patients
  • Older People

Interventions

OTHER

High-flux hemodialysis

High-flux hemodialysis removes small and middle molecular solutes through the mechanism of diffusion.

OTHER

Hemodiafiltration

Hemodiafiltration removes solutes using convection which allows for more epuration of middle molecular solutes.

Sponsors & Collaborators

  • AUB Santé

    lead OTHER

Principal Investigators

  • Mabel Aoun, M.D., M.P.H. · AUB SANTE

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-19
Primary Completion
2026-12-19
Completion
2026-12-19

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07278973 on ClinicalTrials.gov